Clinical trial · Interventional
Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions
Ultrasound Guided Percutaneous Microwave Ablation for Breast Lesions: A Prospective Multicenter Study
NCT02860104CI-TRIAL-00024878unknownPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will perform this study to prospectively analyse the clinical outcome after percutaneous microwave ablation(MWA) of benign and malignant breast lesion under ultrasound (US) guidance.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm of Breast | Breast Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| microwave ablation | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- microwave ablation
- description
- microwave ablation
- interventionNames
- Device: microwave ablation
Primary outcomes (1)
- measure
- reduction in volume
- timeFrame
- 5 year
- description
- the volume reduction ratio (VRR) which was calculated by the following equation: VRR (%) = \[(initial volume - final volume) × 100\]/initial volume.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * breast lesion proved by using core-needle biopsy; * for benign lesions,lesion 1.0 cm or larger in greatest diameter and continually increasing during a half year follow-up; for malignant ones, lesion size 2cm or smaller; * distance of at least 1.0cm to papilla with the patients supine; * the symptoms of local pain, discomfortable or compression considered probably relating to the lesion of breast; * the patient with evidently psychological pressure due to the occurrence of the lesion; * patients unwilling or refused to receive other treatment and presence of an appropriate route for percutaneous puncture under US guidance. Exclusion Criteria: * patients who were pregnant or breast-feeding; * patients with evidence of coagulopathy or acute or severe pulmonary insufficiency or heart dysfunction; * patients during menstrual period; * patients who wanted to undergo other therapies including surgical excision and vacuum-assisted biopsy.
References
Publications (2)
- DERIVEDYang Q, Li H, Chen BH, He GZ, Wu XP, Wang LX, Wu H, Dou JP, Han ZY, Zhang J, Yu XL, Yu J, Liang P. Ultrasound-guided percutaneous microwave ablation for 755 benign breast lesions: a prospective multicenter study. Eur Radiol. 2020 Sep;30(9):5029-5038. doi: 10.1007/s00330-020-06868-9. Epub 2020 Apr 30. PMID 32356159
- DERIVEDYu J, Wu H, Meng XW, Mu MJ, Dou JP, Ahmed M, Liang P. Ultrasound-guided percutaneous microwave ablation of central intraductal papilloma: a prospective pilot study. Int J Hyperthermia. 2019;36(1):606-612. doi: 10.1080/02656736.2019.1619849. PMID 31179781